What did @weightdoc actually say?
The claim is straightforward: stop a GLP-1, gain the weight back. @weightdoc cited trial data and a newer systematic review to argue that about 60% of lost weight returns within one year of stopping, with regain eventually plateauing at roughly 75% of initial weight loss. The conclusion is that obesity is a chronic disease requiring long-term management, not a short-term fix.
That's a reasonable summary of the evidence, and the framing is more nuanced than most TikTok takes on this topic. Credit where it's due: the creator didn't claim GLP-1s cure anything, and they correctly flagged that some health benefits persist even after partial regain. The reference to a "systemic review" (likely a systematic review published in 2023 or 2024) is where things get slightly murky, because the specific figures cited deserve scrutiny.
Does the science back this up?
Largely, yes. The STEP 4 trial (Rubino et al., 2021, JAMA) is one of the most cited pieces of evidence here. Participants who switched from semaglutide to placebo regained about two-thirds of their lost weight within 52 weeks. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar patterns with tirzepatide, with significant regain after discontinuation.
The 75% plateau figure tracks with a 2024 systematic review published in Obesity Reviews (Wilding et al. group and others), which modeled long-term regain trajectories across multiple GLP-1 trials. The finding that regain slows and plateaus rather than continuing indefinitely is consistent with the physiology: body weight has a defended set point, and after GLP-1 withdrawal, the body returns toward, but not always completely to, its pre-treatment baseline. The 60% within one year figure is also consistent with trial data, though it varies by drug, dose, and individual metabolic profile.
What did they get wrong (or right)?
The 75% plateau figure is reasonable but should carry a confidence interval, not be stated as a flat average. Regain trajectories vary considerably depending on whether patients made lifestyle changes during treatment, their baseline metabolic health, and how long they were on the medication. Presenting one average can mislead viewers into thinking outcomes are uniform.
The creator also glossed over something important: the health benefits they mention retaining are not guaranteed across the board. Cardiovascular risk markers, for example, tend to drift back toward baseline after weight regain (Lingvay et al., 2022, The Lancet). The SELECT trial data (Lincoff et al., 2023, NEJM) showed cardiovascular benefits with ongoing semaglutide use, but that data does not extend cleanly to the post-discontinuation period.
What @weightdoc got right is the core message: obesity behaves like other chronic conditions. The analogy to hypertension or type 2 diabetes, where you don't stop treatment because you feel better, is accurate and clinically appropriate.
What should you actually know?
If you've lost weight on a GLP-1 and are considering stopping, this data matters practically. Weight regain after stopping is the rule, not the exception. The STEP 4 and SURMOUNT-4 trials are not outliers. They reflect a biological reality: GLP-1 receptor agonists work while you take them by suppressing appetite signals and slowing gastric emptying, and those effects reverse when the drug clears your system.
The plateau finding is actually worth paying attention to. It suggests the body doesn't infinitely regain, which has implications for people who need to pause treatment due to cost, surgery, or side effects. But "not all the way back" is not the same as "maintained."
- Regain rates differ between drugs: liraglutide data shows faster and more complete regain than semaglutide in comparative analyses.
- Lifestyle interventions during treatment may modify regain trajectories, though evidence is still limited.
- Cost and access remain the primary reason most patients discontinue, not side effects or choice.
Bottom line: should you trust this take?
Yes, with minor caveats. @weightdoc presented the evidence accurately and avoided the most common GLP-1 TikTok pitfalls: no cure claims, no dose recommendations, no overselling. The 60% and 75% figures are defensible from published data. The framing of obesity as a chronic disease requiring chronic management is consistent with current clinical guidelines from the American Association of Clinical Endocrinology and the Obesity Medicine Association. The missing nuance is that individual regain varies, retained health benefits are not uniform, and stopping is rarely a clean binary choice for most patients.